From July 1, 2023 to September 30, 2023, the company has repurchased 80,000 shares, representing 0.67% for CAD 0.6 million. With this, the company has completed the repurchase of 306,700 shares, representing 2.55% for CAD 2.27 million under the buyback announced on December 13, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.63 CAD | +1.41% | +2.74% | -6.40% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.40% | 72.15M | |
+25.81% | 661B | |
+26.74% | 566B | |
-6.69% | 352B | |
+18.81% | 332B | |
+3.37% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.32% | 145B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.